Primary Objective: To prove the safety of the gynaecological formulation in normal conditions of use.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
32
Treatment duration: 21 consecutive days
Sanofi-Aventis Administrative Office
São Paulo, Brazil
The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.
Time frame: From the treatment start to the end of the study (treatment period 21 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.